Can peptides actually change your clavicle width? Separating looksmax lore from biology

What did @huntr274 actually say?

The creator walked through Dihexa (also spelled "Dehexa" throughout the video) as a synthetic nootropic, making three core claims: it crosses the blood-brain barrier because it is "lipophilic," its half-life is roughly 13 days, and it has potential for "reversing cognitive decline." They acknowledged the carcinogenicity concern but dismissed it quickly, saying "there's no study linking dehexa to cancer." They closed by calling it "one of the most promising synthetic nootropics for long-term cognitive enhancement." The disclaimer at the end was cut off mid-sentence, which is worth noting.

The video is clearly aimed at the looksmax and biohacker communities, not a clinical audience. That framing matters when evaluating what's being glossed over.

Does the science back this up?

Partially, but the optimism is running well ahead of the evidence. Dihexa is a synthetic peptide derived from angiotensin IV, originally developed by Joseph Harding and colleagues at Washington State University. The lipophilicity claim is accurate, and the BBB penetration has been demonstrated in rodent studies. The half-life figure, however, is poorly sourced in the public literature and appears to circulate mainly in nootropic forums rather than peer-reviewed pharmacokinetic data.

The cognitive enhancement research is real but narrow. Harding et al. (2016, Journal of Neurochemistry) showed Dihexa outperformed BDNF in a rodent model of scopolamine-induced memory impairment. That is a meaningful finding in a controlled setting. It is not evidence that the compound reverses human cognitive decline. The leap from "improved synaptogenesis in rats" to "reversing cognitive decline" in people is not a small one. No human clinical trials have been completed or registered as of this writing.

What did they get wrong (or right)?

Credit where it is due: describing Dihexa as "experimental" is accurate and more honest than many nootropic influencers manage. Noting that carcinogenicity is theoretical and not yet study-confirmed is also technically correct, though the framing makes it sound like a cleared concern rather than an open one.

The problems start with the half-life claim. "About 13 days" is repeated confidently, but this number does not appear in any published human pharmacokinetic study. It seems to originate from animal data or community speculation. Stating it as fact is misleading.

More concerning is "reversing cognitive decline." That phrase implies a therapeutic outcome in humans. The existing data is preclinical. Harding's group published promising rodent work, but the compound has not cleared Phase I human trials. Claiming reversal of cognitive decline is not supported by any published human evidence and approaches the kind of disease-treatment framing that has no place in a video about an unscheduled experimental peptide.

The carcinogenicity concern was also undersold. The theoretical risk stems from Dihexa's mechanism as an HGF/MET signaling potentiator. MET receptor overactivation is associated with several cancers in the oncology literature (Organ and Bhatt, 2011, Nature Reviews Cancer). "Theorized" is accurate, but framing it as "thankfully" low-risk glosses over a mechanistically plausible concern.

What should you actually know?

Dihexa sits in a category of compounds that are genuinely interesting to researchers and genuinely risky for unsupervised self-administration. The science behind HGF potentiation and synaptogenesis is not junk. But "interesting to researchers" and "ready for human optimization use" are separated by a large gap that no current human data has bridged.

The carcinogenic risk is not just theoretical in the way that word is often used to mean unlikely. It is mechanistically plausible based on what we know about MET receptor signaling. Anyone considering this compound should understand that distinction clearly. The brain fog reports during loading phases are also not surprising given the compound's mechanism, but they have not been systematically studied.

There are no FDA-approved uses, no established human dosing protocols backed by clinical trial data, and no long-term safety data in humans. If a compound has a plausible cancer mechanism, no human safety trials, and a half-life that means it stays in your system for nearly two weeks, that is not a risk profile to treat casually.